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Comparison of drug retention rates and causes of drug
discontinuation between anti-tumor necrosis factor agents in
rheumatoid arthritis
Abstract
OBJECTIVE: Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to compare
treatment retention rates and specific causes of anti-TNF discontinuation in a population-based RA
cohort. METHODS: All patients treated with etanercept, infliximab, or adalimumab within the Swiss
Clinical Quality Management RA cohort between 1997 and 2006 were included in the study. Causes of
treatment discontinuation were broadly categorized as adverse events (AEs) or nontoxic causes, and
further subdivided into specific categories. Specific causes of treatment interruption were analyzed
using a Cox proportional hazards model and adjusted for potential confounders. RESULTS: A total of
2,364 anti-TNF treatment courses met the inclusion criteria. Treatment discontinuation was reported 803
times: 309 with etanercept, 249 with infliximab, and 245 with adalimumab. Drug inefficacy represented
the largest single cause of treatment discontinuation (55.8% of cases). The median time of receiving
anti-TNF therapy was 37 months, but discontinuation rates differed between the 3 anti-TNF agents (P <
0.001), with shorter retention rates for infliximab (hazard ratio [HR] 1.24, 99% confidence interval
[99% CI] 1.01-1.51). The specific causes of treatment discontinuation revealed an increased risk of AEs
with infliximab (HR 1.4, 99% CI 1.003-1.96), mostly due to an increased risk of infusion or allergic
reactions (HR 2.11, 99% CI 1.23-3.62). Other discontinuation causes were equally distributed between
the anti-TNF agents. CONCLUSION: In this population, infliximab was associated with higher overall
discontinuation rates compared with etanercept and adalimumab, which is mainly due to an increased
risk of infusion or allergic reactions.
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ABSTRACT  
Background: Tumour Necrosis Factor inhibitors (anti-TNF) have revolutionized the treatment of 
severe rheumatoid arthritis (RA), yet drug discontinuation is common. 
Objective: Compare treatment retention rates and specific causes of anti-TNF discontinuation in 
a population-based RA cohort.  
Methods: All patients treated with etanercept (ETA), infliximab (INF) or adalimumab (ADA) 
within the Swiss RA cohort (SCQM-RA) between 1997 and 2006 were included. Causes of 
treatment discontinuation were broadly categorized as ‘adverse events’ (AEs) or as ‘non-toxic 
causes’, and further sub-divided into specific categories. Specific causes of treatment interruption 
were analysed using a Cox proportional hazards model and adjusted for potential confounders. 
Results: A total of 2364 anti-TNF treatment courses met the inclusion criteria. Treatment 
discontinuation was reported 803 times, 325 with ETN, 258 with INF and 221 with ADA. Drug 
inefficacy represented the largest single cause of treatment discontinuation (50 % of the cases). 
The median time on anti-TNF therapy was 37 months, but discontinuation rates differed between 
the 3 anti-TNF agents (ANOVA, p < 0.001), with shorter retention rates for INF (Hazard Rate 
(HR) 1.24 [99% CI 1.01-1.51]). The specific causes of treatment discontinuation revealed an 
increased risk of AEs with INF (HR 1.4 [99% CI 1.003-1.96]), mostly due to an increased risk of 
infusion or allergic reactions (HR 2.11 [99% 1.23-3.62]). Other discontinuation causes were 
equally distributed between the anti-TNF agents. 
Conclusion: In this population, INF was associated with higher overall discontinuation rates 
compared to the other anti-TNF agents, which is mainly due to an increased risk of infusion or 
allergic reactions.   
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The prognosis of RA has improved over the last decades, due to its prompt recognition, the 
systematic introduction of disease modifying antirheumatic drugs (DMARDs) at an early stage of 
the disease, the use of DMARD combinations and the availability of more effective anti-
rheumatic agents. (1-4) 
The development of biologic agents, in particular inhibitors of the tumour necrosis factor (anti-
TNF) during the last decade, represents a major breakthrough for the treatment of severe forms of 
RA (5-8). As it is the case for most active therapies, highly effective interventions raise concerns 
about adverse effects. Controversial data have been published on increased rates of bacterial 
infections and malignancies associated with anti-TNF agents (9-13).  Available anti-TNF agents 
neutralize the TNF in different ways: etanercept (ETA) (Enbrel®, Amgen Inc., Thousand Oaks, 
CA) is a soluble TNF receptor (humanized protein) acting as a competitive inhibitor, while 
infliximab (INF) (Remicade®, Centocor INC., Malvern, PA) or adalimumab (ADA) (Humira®, 
Abbott Laboratories, Illinois, USA) are monoclonal antibodies (chimeric (human IgGк / mouse 
Fυ)  for INF and fully human for ADA) (14, 15). Given these differences, distinct safety profiles 
and efficacy figures might be expected between these agents. Post marketing data have indeed 
suggested an increased risk of  reactivation of latent tuberculosis with monoclonal antibodies 
compared to soluble receptors (16) and suggested that certain anti-TNF agents work better in 
specific chronic inflammatory diseases than others (17, 18). However, it remains unclear how the 
differences affect these agents’ long-term therapeutic effectiveness and their overall tolerability.  
In clinical practice, drug-related side effects, primary non-response or secondary drug resistance 
to anti-TNF agents are common problems (4, 19). Comparative analyses of anti-TNF 
discontinuation rates have generally found no difference between available agents (4). However, 
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comparative studies are sparse, have limited follow-up time and relatively low numbers of 
treatment interruptions. 
The aims of this population-based cohort study are thus 1) to compare the treatment retention 
rates between ETA, INF and ADA and 2) to compare the specific causes of treatment 
discontinuation. 
METHODS AND PATIENTS 
Study Population: This is a longitudinal, observational, population-based cohort study based on 
the Swiss RA registry (SCQM-RA, Swiss Clinical Quality Management for Rheumatoid 
Arthritis). SCQM-RA is a national program designed by the Swiss Society for Rheumatology 
aiming at following longitudinally patients with RA. Patients are assessed at least yearly for 
disease activity, radiographic joint damage, function, quality of life and other patient 
characteristics. Information on current treatment, changes in medication, withdrawal and side 
effects are also reported. An estimated 70-80% of all RA patients on biologic agents of 
Switzerland are included in the registry (4). Approximately half of the patients come from private 
rheumatology practices, 30 % from non-academic hospital centres and 20% from academic 
centres. We included all patients of the database treated with an anti-TNF agent between January 
1997 and December 2006. When the reason for anti-TNF discontinuation was unclear or the dates 
of initiation or discontinuation uncertain in the database, we contacted the treating physician to 
ascertain this information. If he or she did not answer the first mail, a second was sent. Currently, 
no compelling guidelines or administrative restrictions exist in Switzerland, which would favour 
the use of one anti-TNF agent over another or limit dose adjustments of these agents, if needed. A 
study previously published in the same population demonstrated  a clinically significant dose 
escalation  for INF (4). 
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Primary outcome: The primary endpoints of this study were the time to anti-TNF 
discontinuation and the specific causes for drug discontinuation. We first examined the time until 
drug discontinuation independently of the reason that led to drug interruption. Drug 
discontinuation rates or ‘drug survival rates’ indicate both the patients’ and doctors’ satisfaction 
with the therapy and provide a useful summary measure of the overall treatment effectiveness 
and tolerability (20, 21). Drug interruption was defined as the discontinuation of the current anti-
TNF agent for more then 6 months. Temporary interruptions (less than 6 months) were not 
considered a drug discontinuation. We categorized causes of drug discontinuation into adverse 
events (AEs) (acute systemic reaction including acute infusion or systemic allergic reactions, 
dermatologic reactions, infectious complications, malignancies and other miscellaneous reasons) 
and ‘non-toxic causes’ (including treatment ineffectiveness, patient preferences, pregnancy wish 
and remission). Adverse events and other causes of treatment interruptions were attributed to the 
current anti-TNF agent, independently to the previous biologic agent. In order to minimize 
reporting bias by physicians, we chose a priori to consider only AEs severe enough to cause 
treatment discontinuation. Physicians were allowed to cite more than one reason for interrupting 
the anti-TNF agent. 
Exposure of interest: The exposure of interest for this analysis was the type of anti-TNF agent 
received, thus all observations were categorized as ADA, INF or ETA.  
Statistical analysis: Baseline disease characteristics were compared across the three anti-TNF 
agents. For continuous variables, the significance of differences in mean values was assessed 
with one-way analysis of variance (ANOVA) for normally distributed variables and with the 
Kruskal-Wallis test for non-normally distributed variables. For binary variables, Pearson’s Chi-
square test was used to evaluate the significance of differences in proportions. All statistical tests 
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were two-sided and evaluated at the 0.05 significance level. The statistical analysis was 
performed with Stata v. 9.2 for Windows (Stata Statistical Software, Texas, USA).  
Confounding was a concern in this analysis, because the choice of an anti-TNF could be 
associated with disease severity or treatment tolerability. Because such an association would 
substantially influence drug discontinuation and the incidence of AEs, we used multivariate 
adjustments to correct for such confounding effects. The time to discontinuation of anti-TNF 
agents was analyzed using a Cox proportional hazards model (22). We then analyzed the 
proportion of treatment discontinuations explained by specific causes. We first examined the 
numbers of events by anti-TNF agent and evaluated the statistical significance of differences in 
proportions using the Pearson’s Chi-square test or the Fisher exact test, when adequate 
(unadjusted analysis). We then analyzed the time to event using Cox proportional hazards model 
and adjusted for potential confounders (adjusted analysis). Survival curves of the time to 
discontinuation (‘drug survival’) or time to event were produced with the Kaplan-Meier product-
limit method (22). 
We identified a priori sex, age, disease duration, baseline disease activity, (DAS28 score), 
baseline functional disability (HAQ score), presence of rheumatoid factor (RF), concomitant 
DMARDs (leflunomide, methotrexate (MTX) or other DMARDs), co-therapy with low dose 
glucocorticoids, failure to a previous anti-TNF and year of anti-TNF introduction (<2001, 2001-
2003, > 2004) as potential confounding factors and corrected for these in the adjusted model. 
Pair-wise comparisons between the 3 treatment groups were planned a priori, but were 
considered only if the overall comparison indicated a significant difference (ANOVA, p < 0.05). 
To maintain a Type I error at 5%, pair-wise comparisons and confidence intervals of therapeutic 
groups were corrected with Bonferroni’s adjustment procedure.  
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RESULTS 
The total person time on anti-TNF agents was 3867 patient-years. Of the 2364 anti-TNF 
treatment courses 78% were on a first course; 882 patients received ADA, 887 ETA, and  
595 INF. The baseline characteristics were consistent between the three anti-TNF groups (table 
1), but for previous anti-TNF failure (lower in patient on ETA, p<0.001) and concomitant MTX 
use (higher in patients on INF, p<0.001). These differences were expected as ETA was the first 
anti-TNF agent on the market in Switzerland and concomitant MTX is generally used in 
combination with INF. Eight hundred and three anti-TNF discontinuation were reported; of 
which 245 for ADA, 309 for ETA and 249 for INF. In about half of the anti-TNF 
discontinuations the specific motive for interrupting therapy was unclear from the database (448 
out of 803), but in 298 cases (298 out of 448) the motive for anti-TNF discontinuation could be 
elucidated after contacting the treating rheumatologist, but in 19% of cases (150 out of 803; ETA: 
72, ADA, 32, INF: 47) the exact reason remained unclear (patient lost to follow-up, no answer 
from the physician to several mailings). Ultimately, 81% of the causes of treatment 
discontinuation (653 out of 803) could be retrieved and included in the analysis. The baseline 
characteristics of patients without specific cause of anti-TNF interruption did not differ from the 
others and was mainly related to the physician in charge Mean age was 53      [±14] years 
(p=0.36), disease duration 10.8 [± 9.6]  years ( p=0.51), baseline DAS score   4.38 [±4.4] 
(p=0.88), baseline HAQ 1.35 [±0.71]  (p=0.61), concomitant Methotrexate 46%(p=0.16), 
concomitant Leflunomide 21% (p=0,09), other DMARD 21% (p=0.7).  
The median drug survival time for anti-TNF was of 37 months [IQR 13- 57]. Treatment 
discontinuation due to AEs occurred on average after 11 months [IQR 4-19], which is 
significantly shorter than for non-toxic causes of treatment discontinuation, occurring after 18 
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months [IQR 6-24] (p<0.001). A statistical significant difference was noted in the discontinuation 
rates between the three anti-TNF agents (crude p=0.04, adjusted p<0.001, Figure 1). INF was 
associated with the highest treatment discontinuation rate (crude hazard ratio (HR): 1.19 [99% 
confidence interval (CI): 0.98-1.45]), adjusted HR 1.24 [99% CI: 1.01-1.51]), Figure 1). Time to 
anti-TNF discontinuation because of an AE was significantly different between the three anti-
TNF agents in disfavour of INF (ANOVA p=0.02, Figure 2, HR 1.4 [99%CI: 1.003-1.96]), while 
no differences existed in treatment discontinuation for the non toxic causes (ANOVA p=0.38, 
Figure 3). Strong confounders of the overall discontinuation rate proved to be a history of 
previous failure on anti-TNF and the year of treatment initiation. Median drug survival was the 
longest for the first anti-TNF agent (37 months [IQR 13-57]) and decreased with subsequent anti-
TNF agents (21 months (IQR 11-40) for the second anti-TNF agent, 13 months (IQR 6-29) for 
the third anti-TNF agent). Anti-TNF agents started before 2000 had a median survival time of 43 
months, compared to 37 months in the years 2001-2004 and 26 months after 2005. Other 
significant predictors for treatment discontinuation included absence of concomitant 
glucocorticoids (HR 1.69 [95% CI 1.46-1.95] and high baseline DAS28 levels (HR 1.09 [95% 
CI: 1.02-1.16]). We also found a trend in favour of a lower risk of anti-TNF discontinuation for 
anti-TNFs in combination with MTX (HR 0.85 [95% CI 0.70-1.02]). After adjusting for these 
variables in the multivariate analysis, the relative risk for treatment discontinuation of ADA 
compared to INF was significantly modified (crude HR 0.87 [99% CI: 0.70-1.10], adjusted HR 
0.74 [99% CI 0.59-0.92]), suggesting that a history of previous anti-TNF failure and the year of 
treatment initiation particularly affected ADA treatment maintenance. After one year of anti-TNF 
initiation, 78% of the patients were still on INF, 82% on ETA and 84% on ADA. At two years, 
58% were on INF, 65% on ETA and 66% on ADA (Figure 1).  
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Overall, AEs were responsible for treatment discontinuation in 47% of cases (318 of 653 cases): 
16% for acute systemic reactions (105 cases), 10% for a dermatological complication (65 cases), 
14% for infections (89 cases), 2% for malignancies (15 cases), and 24% for other miscellaneous 
complications (neurological, ophtalmological, cardiovascular, pulmonary, gastroenterological, 
renal, haematological and osteoarticular) (157 cases). Non-toxic causes were responsible for 
treatment discontinuation in 61% of cases (397 out of 653 cases). Treatment inefficacy 
represented the largest single cause for anti-TNF treatment discontinuation: 50% (327 cases). At 
the time of treatment interruption, the mean DAS28 level in this group was of 4.37 [95% CI 4.21-
4.53], compared to 3.78 [95% CI 3.66-3.90] for patients with other causes of treatment 
discontinuation (p<0.001). Other non-toxic causes included patient preference in 8.8 % (58 
cases), followed by remission in 2.9% (19 cases) and finally, pregnancy (wish) in 1.1% (8 cases). 
Of note, physicians could motivate anti-TNF discontinuation by more than one reason, explaining 
why the total exceeds 100%.  
The proportion of overall AEs causing treatment discontinuation did not differ significantly 
between the three anti-TNFs (p=0.093, table 2), although slightly more AEs were reported as 
cause for treatment discontinuation with INF (52%) compared to the other two agents (~43 and 
49%). Similar results were seen when taking into account the time to AE and adjusting for 
differences in baseline risk factors (table 3), with an increased overall risk of AEs with INF (HR 
1.4 [99% CI 1.00-1.96]) compared to the other two agents. An analysis of the specific types of 
AEs revealed significantly more acute systemic reactions with INF (crude p< 0.001, adjusted 
p=0.018, HR for INF 2.11 [99% IC 1.23-3.62]). No significant difference between the three anti-
TNF agents existed for dermatological AEs (adjusted p=0.81), infectious AEs (adjusted p=0.18) 
or malignancies (adjusted p=0.21). The types of infections causing treatment discontinuation 
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were diverse and included: respiratory tract infections (12 of which 6 pneumonias), urogenital 
tract infections (8), osteomyelitis (4), viral infections (2 herpes simplex 1, one  chicken pox), 
cutaneous infections (3), gastrointestinal infections (3), septicaemia (2), ENT infections (2), 
lymphangitis (2), pneumocystis jirovecii (2) and other rare infections. Four cases of 
mycobacterial infections were reported, two with Mycobacteria (MB) tuberculosis, one with MB 
kanzasii, and one with MB fortuitum, and no MB infection was associated with ETA. In certain 
cases, the recurrence of infectious AEs (cystitis, respiratory tract infections) more than the 
severity of the disease was the cause of treatment discontinuation. Fifteen cases of malignancies 
led to anti-TNF discontinuation. The most common malignancies were: breast cancers (2 cases 
with ETA and ADA), lymphomas (2 cases with ETA and ADA), and uro-genital malignancies (2 
cases with ETA and INF).  
DISCUSSION 
This study demonstrates a statistically significant difference in discontinuation rates between the 
three anti-TNF agents, with shorter drug retention, and an increased risk of AEs in patients 
treated with INF, mainly due to a higher risk of infusion and systemic allergic reactions. Other 
discontinuation causes were equally distributed across the three anti-TNF agents. Analyses from 
the British Biologic Register also suggested a higher discontinuation rate of INF (42%) compared 
to ADA (30%) and ETA (29%) during a first course of anti-TNF (23). Bocqu et al. also found 
better retention rates with ETA (p=0.0001) and ADA (p=0.01) than with INF at one year (24). 
Similarly, Kristenson et al. suggested a difference of anti-TNF retention at five years between 
ETA (65%) and INF (36%) (p<0.001) when combined with MTX (25). However, other analyses, 
found similar retention rates of available anti-TNF agents in RA (26, 27). The small number of 
patients included in these studies probably explains part of these discrepancies. In the literature, 
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anti-TNF treatment survival was shown to be prolonged when combined with MTX (25, 28). 
Although we found a trend in favour of a lower risk of anti-TNF discontinuation for anti-TNFs in 
combination with MTX (HR 0.85 [95% CI 0.70-1.02]), this result did not reach statistical 
significance (p=0.08). In addition, we observed that a relevant predictor of treatment interruption 
was the absence of concomitant use of glucocorticoid (HR 1.69 [95% CI 1.46-1.95]). While a 
decreased risk of infusion reactions with low dose glucocorticoids has been described in patients 
receiving  INF (29), a potential increase of anti-TNF maintenance by low-dose glucocorticoids is 
of practical importance but needs to be confirmed in other patient populations.  
The most frequent single cause for anti-TNF discontinuation in our study was treatment 
inefficacy, which was not significantly different between the three anti-TNF agents. Which of 
treatment ineffectiveness or overall AEs is the primary cause of anti-TNF discontinuation  
remains of debate in the literature (23, 26, 30, 31). Moreover, we noted that drug survival was 
inversely proportional to previous anti-TNF failure and later year of treatment initiation. The 
inverse association with calendar year of treatment initiation reflects the greater availability of 
therapeutic alternatives favouring treatment switches over time and the increasing proportion of 
patients starting biologics after having failed previous anti-TNF agents (4).  Switching once anti-
TNF (from a soluble receptor to a  monoclonal antibody  or vice versa) is supported by the 
literature(23, 32-34)  , but switching a second time seems much less effective  (32), which is 
demonstrated in our study by very short treatment retention with a third anti-TNF agent (median 
retention time of only 13 months (IQR 6-29)). 
INF was associated with a higher discontinuation rate due to AEs (HR 1.4 [99% CI 1.003-1.96]) 
compared to ADA and ETA, which was mainly due to an increased incidence of acute systemic 
reactions (HR 2.15 [99% CI 1.24-3.7]). No difference between anti-TNF agents was reported 
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with regards to infections, malignancies and dermatological complications. Furthermore, no 
differences were found in the incidence of other non-toxic causes of treatment discontinuation 
(remission, pregnancy (wish) and patient preference). Baseline characteristics between anti-TNF 
agents were fairly similar and do not explain the difference in drug discontinuation or incidence 
of AEs. Overall, these results suggest that available anti-TNF agents do not differ in their 
effectiveness to control RA, but may differ in their incidence of specific AEs. In particular, acute 
systemic reactions caused more often treatment interruption with INF, which could be related to 
the structure (chimeric component) and the IV administration of INF. 
In the literature, the risk of acute infusion reactions with INF varies considerably (between 0.8 to 
8.8 % per infusion) and affects approximately between 10 to 23% of patients per year (35-40). 
Cheifetz et al. distinguished acute infusion reactions occurring within 24 hours and delayed 
infusion reactions occurring between 1 to 14 days after therapy (38). Delayed infusion reactions 
occur in about 2% of the patients per year (38, 39) and resemble closely a “serum sickness like” 
reaction. Others have concluded that patients having developed human anti-chimeric antibodies 
(HACA) are more susceptible to develop acute allergic reactions (41). Moreover, the presence of 
positive baseline antinuclear antibodies and the absence of concomitant use of MTX have also 
been demonstrated to increase the risk of infusion reactions (42). Because ETA and ADA are 
administered subcutaneously, allergic reactions to these two agents are more likely to be 
categorized as ‘dermatological reaction’ by treating physicians, which could have created some 
misclassification. In a sensitivity analysis, we combined the dermatological and acute systemic 
reaction categories, and still found a significant hazard for this combined AE category with INF 
(HR 1.69 [99% CI 1.05-2.72]), which suggests that overall allergic reactions remain a more 
common cause of treatment discontinuation for INF.   
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The risk of infection was similar  for the three drugs. The spectrum of infections reported in this 
study is similar to that found in literature (respiratory tract, skin and soft tissue, bone and joint, 
urinary tract infections), although we did not see an increased incidence of skin and soft tissue 
infections, as has been suggested by others (11, 43). A difference in susceptibility to MB 
infections between the monoclonal antibodies and the soluble receptor has also been described 
(16). A recent study demonstrated a HR of 10 [95%CI 1.92-52.61] for the risk of tuberculosis 
reactivation in patients treated with monoclonal antibodies anti-TNF agents as compared to those 
receiving ETA (44). Although the incidence of MB infections was too low in our population to 
demonstrate significant differences between these agents, we found no MB infections in the ETA 
group. Furthermore, no significant difference could be demonstrated in solid or lymphomatous 
tumours between the anti-TNF agents. These findings are similar to those previously published in 
the literature (27, 45). The dosages of anti-TNF agents in patients presenting a malignancy were 
not different from those used in the rest of the study population.    
In 19 % of the treatment discontinuations, the specific reason for anti-TNF interruption could not 
be retrieved, generally due to a lack of response from the physician in charge. We do not think 
this confounds our results, because missing information is primarily related to the doctor in 
charge and not to disease characteristics of these patients. Patients missing the specific cause of 
treatment interruption had similar disease and treatment characteristics than the rest of the 
population. Since this is an observational study, there is a potential for selection bias between 
treatment groups. However, the baseline characteristics were relatively homogeneous, but for 
expected differences (proportion of previous failures to anti-TNF, MTX use). Furthermore, 
glucocorticoid use is a good proxy for RA disease severity and its prevalence was similar 
between the 3 treatment groups. The physician’s personal preference seemed to be the most 
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involved in the selection of a particular anti-TNF agent. We adjusted the analysis for potential 
confounders (table 1); however we cannot exclude confounding by unmeasured factors. To our 
knowledge, this is the first cohort  study to directly compare the specific causes of treatment 
discontinuation between the available anti-TNF agents. It is a, population-based study, which 
minimizes potential selection biases and allowed to adjust the analysis for important confounding 
factors. The specific causes of treatment discontinuation were reported by the physician in charge 
of the patient. Inefficacy was the most frequent cause of treatment discontinuation.  Definition for 
inefficacy is ill defined in the literature (46) and remains largely physician –dependant. We did 
not analyse transitory causes of treatment discontinuation in order to minimize reporting bias, 
frequent for expected AEs.   
This study found a higher discontinuation rate for patients treated with INF than with the other 
anti-TNF agents. The shorter treatment retention is primarily explained by a higher risk of 
infusion reactions or acute systemic reactions. Furthermore, with similar rates of treatment 
discontinuation for inefficacy across all 3 agents, this study suggests no difference in 
effectiveness between the 3 anti-TNF agents. Given the protective effect of glucocorticoids on 
infusion reactions with INF (29), and the longer treatment survival of INF if combination with 
MTX, our results suggest that ETA or ADA may be considered preferentially for patients 
unwilling or unable to take MTX or glucocorticoid co-therapy.  
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Table 1: Baseline characteristics of the study population  
Baseline characteristics 
 
 
INF 
(N=595) 
ETA 
(N=887) 
ADA 
(N=882) 
P* 
Age§ [years] 
 
53 ±13 54 ±14 55 ± 13 0.16 
Gender,  male  [%] 
 
24 22 21 0.42 
Disease duration* [years] 
 
10 ± 9 10 ± 9 10 ± 9 0.2 
RF [%] 
 
77 74 75 0.88 
Failure to previous anti-TNF [%] 
 
23% 19% 27% <0.001
DAS 28* 
 
4.27 ±1.52 4.23 ±1.53 4.14 ±1.42 0.066 
RADAI* 
 
4.29 ±2.14 4.31 ±2.24 4.16 ±2.15 0.37 
HAQ* 
 
1.32 ±0.72 1.25 ±0.76 1.17 ± 0.71 0.117 
DMARDs #               N ( %) 
 
Methotrexate 
Leflunomide 
Other 
No DMARD 
 
 
 
439 (74) 
99 (17) 
101 (17) 
67 (11) 
 
 
486 (55) 
151 (17) 
164 (19) 
252 (29) 
 
 
541 (61) 
160 (18) 
181 (20) 
195 (22) 
 
 
<0.001
0.765 
0.246 
0.000 
Glucocorticoid           N (%) 
 
312  (52) 460  (52) 439  (49) 0.409 
 
Legend Table 1: 
§ mean ±SD; * one way analysis of variance (ANOVA) of means for continuous variables;          
# patients could have more than one concomitant DMARD, therefore the total could exceed 
100%. INF = infliximab, ETA = etanercept, ADA = adalimumab, RF = rheumatoid factor; anti-
TNF = anti-tumour necrosis factor inhibitor; DAS 28 = 28-joint Disease Activity Score; RADAI 
= rheumatoid arthritis disease activity index; HAQ =  Standford Health Assessment 
Questionnaire ; DMARDs =  disease-modifying antirheumatic drugs;                                                                     
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Table 2: Causes of treatment discontinuation: Number of events by anti-TNF agent 
(Unadjusted analysis) 
Causes 
Total person-time on drug (years)N 
INF 
1042 
N= 209 
ETA   
1660 
N=237   
ADA1165 
N= 213 
P° 
All Adverse Events 108 (51. 7) 118 (49)    92 (43.2) 0.093 
Acute Systemic Reaction * 50 (23.9) 24 (10) 31 (14.6) <0.001
Infections 26 (12.4) 41 (17) 22 (10.3) 0.088 
Dermatological disease 16 (7.6) 20 (8.4) 29 (13.6) 0.09 
Malignancy 8 (3.8) 5 (2.1) 2 (0.9) 0.12 
Death 2 0 2 0.33 
Miscellaneous complications 46 (22.1) 54 (22.8) 57 (26.8) 0.78 
 General # 14 (6.7) 13 (5.49) 9 (4.2) 0.46 
 Neuropsychiatrical  15 (7.2) 13 (5.49) 21 (9.9) 0.22 
 Ophthalmologic  3 (1.4) 7 (2.9) 2 (0.9) 0.29 
 Ear nose throat  2 (1.0) 3 (1.3) 0 0.29 
 Cardiovascular  7 (3.3) 14 (5.9) 6 (2.8) 0.23 
 Pulmonary  3 (1.4) 10 (4.21) 5 (2.3) 0.22 
 Gastroenterological  11 (5.2) 17 (7.2) 16 (7.5) 0.67 
 Renal disease 4 (1.9)   (2.9) 0 0.03 
 Haematological  2 (1.0) 4 (1.69) 2 (0.9) 0.75 
 Osteoarticular  6 (2.9) 4 (1.69) 4 (1.9) 0.63 
Non toxic causes 111 (53) 148  (63) 138 (64.8) 0.11 
 Ineffectiveness 90 (43) 125 (52) 112 (52.6) 0.17 
 Pregnancy 3 (1.4) 2 (0.8) 2 (0.9) 0.80 
 Remission 5  (2.3) 5 (2.1) 12 (5.6) 0.11 
 Preference 17 (8.1) 23 (9.7) 18 (8.4) 0.90 
Legend table 2 
INF = infliximab, ETA = etanercept, ADA = adalimumab, °chi-square or Fisher test when 
appropriate; * acute systemic reaction included infusion reactions or systemic allergic reactions   
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# general: fatigue, head aches, weight changes…
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Table 3: Causes of treatment discontinuation. Analysis of the time to event (Cox 
proportional hazard model, adjusted analysis) 
Causes INF 
Ref 
         ETA             
    HR [95%CI] § 
         ADA 
    HR [95%CI] § 
p  
 
All Adverse events 
 
1 0.79 [0.55-1.13] 0.67 [0.45-0.97] 0.02 
    Acute syst. reaction #    
 
1 0.4 [0.21-0.78] 0.56 [0.29-1.09] 0.018 
    Dermatological disease 
 
1 0.85 [0.43-1.70] 1.04 [0.54-2.02] 0.81 
    Infection 
 
1 1.14 [0.68-1.92] 0.56 [0.30-1.04] 0.18 
    Malignancy 
 
1 0.54 [0.16-1.85] 0.20 [0.37-1.06] 0.12 
    Miscellaneous 
 
1 0.81 [0.55-1.19] 0.85 [0.58-1.25] 0.55 
All non-toxic causes 
 
1 0.90 [0.64-1.26] 0.82 [0.58-1.18] 0.38 
    Ineffectiveness 
 
1 0.95 [0.71-1.26] 0.82 [0.61-1.11] 0.42 
    Remission 
 
1 0.85 [0.22-3.3  ] 1.10 [0.36-3.44] 0.91 
    Pregnancy wish 
 
1 0.75 [0.10-5.55] 1.89 [0.24- 14.9] 0.95 
    Preference 
 
1 0.68 [0.37-1.45] 0.85 [0.41-1.77] 0.68 
 
Legend table 3 
INF = infliximab, ETA = etanercept, ADA = adalimumab; # acute systemic reaction included  
infusion reaction or systemic allergic reaction; § values are hazard ratio (HR) with 95% 
confidence interval (CI), INF (infliximab) = 1 is the reference (REF); * Cox proportional hazard 
analysis, adjusted for sex, age, disease duration, disease activity score (DAS 28), Standford 
health assessment questionnaire (HAQ), rheumatoid factor, leflunomide, methotrexate, other 
disease modifying antirheumatic drugs (DMARDs), and glucocorticoids. 
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Figure 1: Time to nti-TNF discontinuation 
ANOVA p < 0 .001 
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Time to discontinuation of anti-TNF treatment
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Figure 2: s Time to anti-TNF discontinuation due to adverse event
ANOVA  p = 0.02 
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Time to discontinuation of anti-TNF treatment
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Figure 3 Time to anti-TNF discontinuation due to non-toxic causes 
ANOVA p = 0.38 
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Legends of figures 
 
Figure 1: The Kaplan-Meier curve for time to anti-TNF discontinuation (‘‘drug survival’’). All 
causes of discontinuation were analysed together. The survivor curve was adjusted for RF 
positivity, baseline disease activity scores (DAS28), baseline levels of functional disability 
(HAQ), year of treatment initiation, and failure of previous anti-TNF agents. ADA = 
adalimumab; INF = infliximab; ETA = etanercept. 
Figure 2: The Kaplan-Meier curve for time to anti-TNF discontinuation (‘‘drug survival’’) due to 
adverse effects (AEs). The survivor curve was adjusted for RF positivity, baseline disease activity 
scores (DAS28), baseline levels of functional disability (HAQ), year of treatment initiation, and 
failure to previous anti-TNF agents. ADA= adalimumab; INF = infliximab; ETA= etanercept. 
Figure 3: The Kaplan-Meier curve for time to anti-TNF agent discontinuation (‘‘drug survival’’) 
due to non toxic causes. Non toxic causes included ineffectiveness, remission, pregnancy wish, 
and patient preference. The survivor curve was adjusted for RF positivity, baseline disease 
activity scores (DAS28), baseline levels of functional disability (HAQ), year of treatment 
initiation, and failure to previous anti-TNF agents. ADA = adalimumab; INF = infliximab; ETA 
= etanercept. 
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